Drug Profile
Research programme: viral vaccines - BioDiem
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator BioDiem
- Developer BioDiem; University of Canberra
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Dengue; Hepatitis B; Hepatitis D
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Dengue in Australia
- 16 Jul 2016 No recent reports of development identified for research development in Hepatitis-B in Australia
- 16 Jul 2016 No recent reports of development identified for research development in Hepatitis-D in Australia